Cardiovascular risk factors increase the risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms ...

Protagonist Therapeutics, Inc. (”Protagonist” or the “Company”) announced that an abstract was accepted for presentation at the Plenary Session at the American Society of Clinical Oncology (ASCO) ...

INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.

The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG. Click here to ...

Hany Elmariah, MD, discusses how he sees fedratinib fitting into clincal practice for the treatment of myeloproliferative neoplasms.

Panelists discuss how advancements in understanding myeloproliferative neoplasms are shaping treatment approaches through case studies of intermediate-risk myelofibrosis and advanced polycythemia vera ...

NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of ...

Protagonist Therapeutics, Inc.’s PTGX share price has surged by 6.71%, which has investors questioning if this is right time to sell.

You’ve viewed 1 of 5 articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.

In this fourth part of a discussion with The American Journal of Managed Care®, Andrew Kuykendall, MD, clinical researcher at ...

Disc Medicine, Inc.’s IRON share price has dipped by 11.47%, which has investors questioning if this is right time to buy.

Dosage for Jakafi (ruxolitinib) may vary based on the condition it’s being used to treat. You’ll typically take this drug twice per day. Your doctor may adjust your dosage based on certain ...